Compare PUBM & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PUBM | SLDB |
|---|---|---|
| Founded | 2006 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 406.5M | 464.1M |
| IPO Year | 2020 | 2018 |
| Metric | PUBM | SLDB |
|---|---|---|
| Price | $9.21 | $5.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 11 |
| Target Price | ★ $18.45 | $14.82 |
| AVG Volume (30 Days) | ★ 1.1M | 1.1M |
| Earning Date | 11-10-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $288,382,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.49 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.01 | $2.41 |
| 52 Week High | $17.32 | $7.37 |
| Indicator | PUBM | SLDB |
|---|---|---|
| Relative Strength Index (RSI) | 54.40 | 61.97 |
| Support Level | $8.91 | $4.92 |
| Resistance Level | $9.24 | $5.45 |
| Average True Range (ATR) | 0.35 | 0.37 |
| MACD | -0.00 | 0.16 |
| Stochastic Oscillator | 61.62 | 81.91 |
PubMatic Inc is a supply-side platform provider in the digital advertising technology market. These platforms help publishers, which supply digital ad inventory, manage their inventory, selling a high percentage of their inventory (increase the ad fill rate) and maximizing revenue per ad sold (optimize yield). The company generates revenue mainly by taking a piece of the ad sales that it enables. Buyers on the platform include intermediary buyers, such as demand-side platforms, or advertisers and ad agencies directly. Geographically, the company generates the majority of its revenue from the United States, followed by EMEA and APAC.
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.